Search
Aprepitant
go.drugbank.com/drugs/DB00673ApprovedInvestigationalAprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and r...
Unoprostone
go.drugbank.com/drugs/DB06826ApprovedWithdrawnUnoprostone isopropyl is a prostaglandin analogue. Ophthalmic Solution 0.15% is a synthetic docosanoid. Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate....
Barbexaclone
go.drugbank.com/drugs/DB09001ExperimentalBy weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. … Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine.
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedA thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharma...
DOTMP HO-166
go.drugbank.com/drugs/DB05380ExperimentalIt is an experimental therapy that is being developed by NeoRx Corporation.
Queuine
go.drugbank.com/drugs/DB14732ExperimentalNutraceuticalAll eukaryotic organisms, including humans, transform queuine to queuosine by placing it in the wobble position (anticodon) of several tRNAs including aspartic acid, asparagine, histidine, and tyrosine
TAS-102
go.drugbank.com/drugs/DB08937InvestigationalTrifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.
Malacidin A
go.drugbank.com/drugs/DB14051ExperimentalMalacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].
Seliciclib
go.drugbank.com/drugs/DB06195InvestigationalDeveloped by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation